A. Langsted

发表

Exome-wide association study of plasma lipids in >300,000 individuals

Raquel S. Sevilla, Dajiang J. Liu, Chad A. Cowan, 2017, Nature Genetics.

Nonfasting versus fasting lipid profile for cardiovascular risk prediction.

B. Nordestgaard, A. Langsted, 2019, Pathology.

Lipoprotein(a) and Body Mass Compound the Risk of Calcific Aortic Valve Disease.

B. Nordestgaard, P. R. Kamstrup, A. Langsted, 2022, Journal of the American College of Cardiology.

Low and high pancreatic amylase is associated with pancreatic cancer and chronic pancreatitis

B. Nordestgaard, C. M. Madsen, A. Varbo, 2021, European Journal of Epidemiology.

Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study

B. Nordestgaard, A. Langsted, M. Mortensen, 2020, BMJ.

VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins.

B. Nordestgaard, G. Davey Smith, A. Varbo, 2020, Journal of the American College of Cardiology.

Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study.

B. Nordestgaard, A. Langsted, M. Kaltoft, 2020, European heart journal.

The Christmas holidays are immediately followed by a period of hypercholesterolemia.

B. Nordestgaard, C. Kobylecki, S. Vedel-Krogh, 2019, Atherosclerosis.

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.

F. Kronenberg, J. Borén, A. von Eckardstein, 2020, Atherosclerosis.

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

F. Kronenberg, J. Borén, A. von Eckardstein, 2019, Clinical chemistry and laboratory medicine.

Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014.

B. Nordestgaard, A. Langsted, J. Freiberg, 2017, Atherosclerosis.

Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: The Copenhagen General Population Study.

L. Køber, P. R. Kamstrup, K. Kofoed, 2021, Atherosclerosis.

DIAGNOSING PERICARDITIS DUE TO COVID-19 VACCINATION

A. Nsair, A. Langsted, B. Nordestgaard, 2022, Journal of the American College of Cardiology.

A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs.

B. Nordestgaard, A. Langsted, T. Doi, 2021, European heart journal.

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.

B. Nordestgaard, A. Langsted, M. Mortensen, 2021, Journal of the American College of Cardiology.

Reply to: "Methodological issues regarding: "A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals"".

B. Nordestgaard, G. Davey Smith, A. Varbo, 2020, Atherosclerosis.

Low high-density lipoprotein cholesterol to monitor long-term average increased triglycerides.

B. Nordestgaard, A. Varbo, A. Jensen, 2019, The Journal of clinical endocrinology and metabolism.

Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans

C. Voermans, E. Stroes, H. Verberne, 2017, Arteriosclerosis, thrombosis, and vascular biology.

Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease.

B. Nordestgaard, A. Varbo, L. Bang, 2016, Clinical chemistry.

Commentary: Nonfasting remnant cholesterol simplifies triglyceride-rich lipoproteins for clinical use, and metabolomic phenotyping ignites scientific curiosity.

B. Nordestgaard, A. Varbo, A. Langsted, 2016, International journal of epidemiology.

Nonfasting hyperlipidemia and cardiovascular disease.

B. Nordestgaard, A. Langsted, J. Freiberg, 2009, Current drug targets.

How Does Elevated Lipoprotein(a) Cause Aortic Valve Stenosis?

B. Nordestgaard, A. Langsted, 2015, Journal of the American College of Cardiology.

Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy

A. Langsted, B. Nordestgaard, 2021, Current Atherosclerosis Reports.

Antisense Oligonucleotides Targeting Lipoprotein(a)

B. Nordestgaard, A. Langsted, 2019, Current Atherosclerosis Reports.

Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia

B. Nordestgaard, A. Langsted, 2022, Current Atherosclerosis Reports.

High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.

B. Nordestgaard, M. Benn, P. R. Kamstrup, 2016, The lancet. Diabetes & endocrinology.

Lipoprotein(a) Should Be Measured in All Individuals Suspected of Having Familial Hypercholesterolemia.

B. Nordestgaard, A. Langsted, 2019, Clinical chemistry.

Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk.

B. Nordestgaard, P. R. Kamstrup, A. Langsted, 2014, Atherosclerosis.

In reply to letter to editor by Reaven ‘Is insulin resistance the link between TG‐rich lipoproteins and excess death?’

B. Nordestgaard, A. Langsted, 2011 .

Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?

B. Nordestgaard, A. Langsted, 2020, Current opinion in lipidology.

Lp(a) (Lipoprotein[a])-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.

B. Nordestgaard, C. M. Madsen, A. Varbo, 2019, Arteriosclerosis, thrombosis, and vascular biology.

Response to 'Lipoprotein(a): it is not the cholesterol content: it is the apolipoprotein(a)!'

B. Nordestgaard, P. R. Kamstrup, A. Langsted, 2019, European heart journal.

Lipoprotein(a) during COVID-19 hospitalization: Thrombosis, inflammation, and mortality

B. Nordestgaard, S. F. Nielsen, K. Iversen, 2022, Atherosclerosis.

Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study.

B. Nordestgaard, P. R. Kamstrup, A. Langsted, 2021, European heart journal.

Elevated lipoprotein(a) in mitral and aortic valve calcification and stenosis: The Copenhagen general population study

K. Kofoed, J. T. Kühl, A. Langsted, 2021, Atherosclerosis.

G. Davey Smith, A. Langsted, S. Afzal, 2022, Journal of the American College of Cardiology.

Reply to: "Seasonal variations of lipid profiles in a French cohort".

B. Nordestgaard, C. Kobylecki, S. Vedel-Krogh, 2019, Atherosclerosis.

ApoB and Non‐HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk

B. Nordestgaard, A. Langsted, M. Mortensen, 2022, Annals of neurology.

Lipoprotein(a) and familial hypercholesterolaemia - Authors' reply.

B. Nordestgaard, M. Benn, P. R. Kamstrup, 2016, The lancet. Diabetes & endocrinology.

The need to focus on primary health care for chronic diseases

B. Nordestgaard, M. Benn, P. R. Kamstrup, 2016 .

Obesity, Triglycerides, Remnant Cholesterol, and Other Causal Factors in Aortic Valve Stenosis: A Review

B. Nordestgaard, A. Langsted, M. Kaltoft, 2022, CardioMetabolic Syndrome Journal.

Hypertriglyceridemia and Pancreatitis-New Evidence That Less Is More-Reply.

B. Nordestgaard, A. Langsted, S. B. Pedersen, 2017, JAMA internal medicine.

Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study.

B. Nordestgaard, A. Varbo, P. R. Kamstrup, 2020, Journal of the American College of Cardiology.

Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medi

F. Kronenberg, J. Borén, A. von Eckardstein, 2016, Clinical chemistry.

Chylomicronemia risk factors ranked by importance for the individual and community in 108 711 women and men

B. Nordestgaard, A. Varbo, S. Pedersen, 2018, Journal of internal medicine.

A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals.

B. Nordestgaard, G. Davey Smith, A. Varbo, 2019, Atherosclerosis.

Elevated Lipoprotein(a) and Risk of Ischemic Stroke.

B. Nordestgaard, P. R. Kamstrup, A. Langsted, 2019, Journal of the American College of Cardiology.

Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study.

B. Nordestgaard, A. Langsted, 2011, Clinical chemistry.

Mineral oil and icosapent ethyl may jointly explain the between arm difference of cardiovascular risk in REDUCE-IT.

B. Nordestgaard, A. Langsted, T. Doi, 2021, European heart journal.

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

B. Nordestgaard, A. Langsted, 2016, Journal of Lipid Research.

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease.

B. Nordestgaard, E. Schmidt, A. Langsted, 2022, Journal of the American College of Cardiology.

High lipoprotein(a) and high risk of mortality.

B. Nordestgaard, P. R. Kamstrup, A. Langsted, 2019, European heart journal.

High Lipoprotein(a) and Low Risk of Major Bleeding in Brain and Airways in the General Population: a Mendelian Randomization Study.

B. Nordestgaard, P. R. Kamstrup, A. Langsted, 2017, Clinical chemistry.

Elevated LDL Triglycerides and Atherosclerotic Risk.

B. Nordestgaard, G. Davey Smith, A. Varbo, 2023, Journal of the American College of Cardiology.

Antiplatelet therapy: Pharmacogenomic approach to tailor drug therapy

B. Nordestgaard, S. Nicholls, A. Tybjærg‐Hansen, 2018, Nature Reviews Cardiology.

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med

F. Kronenberg, J. Borén, A. von Eckardstein, 2016, Clinical chemistry.

Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting

N. Wareham, B. Nordestgaard, K. Khaw, 2018, European heart journal.

Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction

B. Nordestgaard, A. Langsted, J. Freiberg, 2008, Circulation.

Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease?

B. Nordestgaard, A. Langsted, T. Doi, 2023, Current opinion in endocrinology, diabetes, and obesity.

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

F. Kronenberg, J. Borén, A. von Eckardstein, 2018, Clinical chemistry.

Reply to: "Appropriate use of cholesterol-lowering therapy".

B. Nordestgaard, A. Langsted, J. Freiberg, 2017, Atherosclerosis.

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis

James R. Staley, Daniel F. Freitag, J. Danesh, 2018, JAMA cardiology.

Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis.

Børge G Nordestgaard, B. Nordestgaard, A. Langsted, 2016, JAMA internal medicine.

Contribution of remnant cholesterol to cardiovascular risk

B. Nordestgaard, C. M. Madsen, A. Langsted, 2020, Journal of internal medicine.

AHRR hypomethylation as an epigenetic marker of smoking history predicts risk of myocardial infarction in former smokers.

S. Bojesen, B. Nordestgaard, E. Stroes, 2020, Atherosclerosis.

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.

B. Nordestgaard, M. Benn, P. R. Kamstrup, 2016, The Journal of clinical endocrinology and metabolism.

Nonfasting Lipid Profiles: The Way of the Future.

B. Nordestgaard, A. Langsted, 2015, Clinical Chemistry.

Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow‐up

P. Schnohr, G. Jensen, A. Tybjærg‐Hansen, 2011, Journal of internal medicine.

Obesity as a Causal Risk Factor for Aortic Valve Stenosis.

B. Nordestgaard, A. Langsted, M. Kaltoft, 2020, Journal of the American College of Cardiology.

Smoking as the most important risk factor for chronic pancreatitis in the general population

B. Nordestgaard, A. Langsted, Signe E J Hansen, 2023, European Journal of Epidemiology.

Smoking is Associated with Increased Risk of Major Bleeding: A Prospective Cohort Study

B. Nordestgaard, A. Langsted, 2018, Thrombosis and Haemostasis.

Obesity As A Causal Risk Factor For Aortic Valve Stenosis

A. Langsted, B. Nordestgaard, M. Kaltoft, 2019, Atherosclerosis.

Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population.

B. Nordestgaard, A. Varbo, P. R. Kamstrup, 2015, The Journal of clinical endocrinology and metabolism.

Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.

A. Langsted, B. Nordestgaard, T. Doi, 2023, Atherosclerosis.

Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms.

B. Nordestgaard, A. Varbo, A. Langsted, 2023, Clinical chemistry.

Small Dense Low‐Density Lipoprotein Cholesterol and Ischemic Stroke

B. Nordestgaard, A. Varbo, P. R. Kamstrup, 2023, Annals of neurology.

Reply: Peculiar Paradoxical Results That Puzzle Me.

G. Davey Smith, A. Langsted, B. Nordestgaard, 2021, Journal of the American College of Cardiology.

Very low-density lipoprotein cholesterol may mediate a substantial component of the effect of obesity on myocardial infarction risk: the Copenhagen General Population Study

B. Nordestgaard, S. F. Nielsen, G. Davey Smith, 2020 .

How Does Elevated Lipoprotein(a) Cause Aortic Valve Stenosis?

B. Nordestgaard, A. Langsted, 2015, Journal of the American College of Cardiology.

B. Nordestgaard, A. Varbo, P. R. Kamstrup, 2015, The Journal of clinical endocrinology and metabolism.

Nonfasting Lipid Profiles: The Way of the Future.

B. Nordestgaard, A. Langsted, 2015, Clinical chemistry.

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

F. Kronenberg, J. Borén, A. von Eckardstein, 2019, Clinical chemistry and laboratory medicine.

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

F. Kronenberg, J. Borén, A. von Eckardstein, 2018, Clinical chemistry.

Elevated Lipoprotein(a) and Risk of Ischemic Stroke.

B. Nordestgaard, P. R. Kamstrup, A. Langsted, 2019, Journal of the American College of Cardiology.

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans

B. Nordestgaard, A. Langsted, Takahito Doi, 2023, Journal of atherosclerosis and thrombosis.

Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study.

B. Nordestgaard, A. Langsted, M. Mortensen, 2022, Atherosclerosis.

Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment.

A. Langsted, A. Wulff, B. Nordestgaard, 2024, Current atherosclerosis reports.

Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study

B. Nordestgaard, A. Langsted, C. Johannesen, 2021, BMJ.

Acute idiopathic pericarditis during a national lockdown to prevent transmission of SARS-COVID-19

A. Langsted, Nicola C. Edwards, Tom Pasley, 2024, IJC Heart & Vasculature.

Worldwide Increasing Use of Nonfasting Rather Than Fasting Lipid Profiles.

B. Nordestgaard, A. Langsted, 2024, Clinical chemistry.

Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure

M. Benn, A. Tybjaerg-hansen, A. Langsted, 2016 .

Lipoprotein(a) and cardiovascular disease

A. Langsted, R. Pandey, K. Sodhi, 2024, The Lancet.